We are international
Donate
• treatment options TEXT SIZE   
imwg guidelines    back

International Myeloma Working Group (IMWG) Molecular Classification of Multiple Myeloma
07.09.10

4 Comments

Would like to know if you would recommend IGH/MYEOV probe over IGH/CCND1 probe for MM panel?

For a faster response, please contact the hotline at:

800-452-2873
M-Th: 9-4 PST
Fri: 9-2 PST

Thanks!
-The IMF

Hello, I would like to know if this is current information as it appears to have been updated in July, 2010. Thank you.

Hello,

I too am looking for updated genetic risk stratification information. Will these be reviewed anytime soon?

Kind Regards

Leave a comment

 related articles
Management of Treatment-Emergent Peripheral Neuropathy
Allogeneic Stem Cell Transplant
Molecular (Genetic) Classification
Serum Free Light Chain Analysis
Response Criteria
Prevention of Blood Clots (Thromboembolic Events)
Vertebral Augmentation
Treatment of Older Patients/Ineligible for Transplant
Diagnosis and Diagnostic Work-up of Myeloma
Requirements for a Myeloma Specialty Center (Facilities and Services)
Imaging Techniques for Diagnosis and Monitoring
Bisphosphonate Therapy (Zometa and Aredia)


You might also be interested in:

Management of Treatment-Emergent Peripheral Neuropathy
Strategies for managing PN include early and regular monitoring, dose modification, and treatment discontinuation.

Allogeneic Stem Cell Transplant

Molecular (Genetic) Classification

Serum Free Light Chain Analysis

Response Criteria

Prevention of Blood Clots (Thromboembolic Events)

Vertebral Augmentation

Treatment of Older Patients/Ineligible for Transplant

Diagnosis and Diagnostic Work-up of Myeloma

Requirements for a Myeloma Specialty Center (Facilities and Services)

Imaging Techniques for Diagnosis and Monitoring

Bisphosphonate Therapy (Zometa and Aredia)